June 27, 2011 (San Diego, California) — Linagliptin shows similar efficacy to glimepiride for the treatment of patients with type 2 diabetes, in terms of controlling blood glucose and glycosylated ...
Linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk for a composite cardiovascular or renal outcome over a median 2.2 years. In adults with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results